ZA200207341B - Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7a]indole compounds. - Google Patents

Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7a]indole compounds.

Info

Publication number
ZA200207341B
ZA200207341B ZA200207341A ZA200207341A ZA200207341B ZA 200207341 B ZA200207341 B ZA 200207341B ZA 200207341 A ZA200207341 A ZA 200207341A ZA 200207341 A ZA200207341 A ZA 200207341A ZA 200207341 B ZA200207341 B ZA 200207341B
Authority
ZA
South Africa
Prior art keywords
diazepino
tetrahydro
novel
indole compounds
indole
Prior art date
Application number
ZA200207341A
Other languages
English (en)
Inventor
Michael Dalton Ennis
Nabil B Ghazal
Robert Louis Hoffmann
Rebecca M Olson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA200207341B publication Critical patent/ZA200207341B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
ZA200207341A 2000-03-14 2002-09-12 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7a]indole compounds. ZA200207341B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18910300P 2000-03-14 2000-03-14

Publications (1)

Publication Number Publication Date
ZA200207341B true ZA200207341B (en) 2004-01-21

Family

ID=22695943

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200207341A ZA200207341B (en) 2000-03-14 2002-09-12 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7a]indole compounds.

Country Status (13)

Country Link
US (2) US6734301B2 (fr)
EP (1) EP1328525A2 (fr)
JP (1) JP2003529569A (fr)
CN (1) CN1418216A (fr)
AR (1) AR028248A1 (fr)
AU (2) AU4316301A (fr)
CA (1) CA2402472A1 (fr)
HK (1) HK1054740A1 (fr)
MX (1) MXPA02008893A (fr)
NZ (1) NZ521389A (fr)
PE (1) PE20011231A1 (fr)
WO (1) WO2001072752A2 (fr)
ZA (1) ZA200207341B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212760A (pt) * 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
CN102060806A (zh) * 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP2018863B9 (fr) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné et utilisation
WO2009063992A1 (fr) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
KR20110132564A (ko) * 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
US20120172350A1 (en) * 2009-09-11 2012-07-05 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
ES2724531T3 (es) 2011-05-12 2019-09-11 Proteostasis Therapeutics Inc Reguladores de proteostasis
WO2013138753A1 (fr) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Promédicaments de riluzole et leur méthode d'utilisation
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867374A (en) 1968-06-05 1975-02-18 Mcneilab Inc Diazepinoindoles
US3689503A (en) 1970-07-30 1972-09-05 Mcneilab Inc Indole-2-carboxylates
SU460724A1 (ru) 1972-07-24 1989-07-30 Новокузнецкий научно-исследовательский химико-фармацевтический институт Способ получени 2,3-дигидро-1Н-1,4-диазепино-(4,5-а)индол-2-онов
US4210590A (en) 1978-01-06 1980-07-01 Mcneil Laboratories, Incorporated Reduction of indole compounds to indoline compounds
NL8500370A (nl) 1984-02-22 1985-09-16 Sandoz Ag Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.

Also Published As

Publication number Publication date
US6734301B2 (en) 2004-05-11
US20040209870A1 (en) 2004-10-21
US20020002161A1 (en) 2002-01-03
NZ521389A (en) 2005-06-24
AR028248A1 (es) 2003-04-30
AU4316301A (en) 2001-10-08
EP1328525A2 (fr) 2003-07-23
JP2003529569A (ja) 2003-10-07
CN1418216A (zh) 2003-05-14
CA2402472A1 (fr) 2001-10-04
WO2001072752A2 (fr) 2001-10-04
PE20011231A1 (es) 2001-12-06
MXPA02008893A (es) 2003-02-10
WO2001072752A3 (fr) 2003-04-17
AU2001243163B2 (en) 2004-11-04
HK1054740A1 (zh) 2003-12-12

Similar Documents

Publication Publication Date Title
AP2002002695A0 (en) Pyrrolo Ä2,3-dÜpyrimidine compounds
HK1051193A1 (en) (1,4')-Bipiperidine compounds.
AU2001292898A1 (en) Substituted azepino[4,5b)indole derivatives
HK1051037A1 (en) Benzodiazepine derivatives.
ZA200202544B (en) Benzodiazepine derivatives.
EG24814A (en) Novel compounds.
ZA200206198B (en) New aza-indolyl derivatives.
MXPA03004292A (es) Compuesto de lactama.
ZA200003927B (en) 1,2,4,5-tetrahydro-benzo[d]jazepines.
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU4787301A (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
HK1044337A1 (en) Amide compounds.
ZA200108968B (en) New compounds.
HK1051863A1 (en) Indol-3-yl derivatives.
ZA200207341B (en) Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7a]indole compounds.
HK1037619A1 (en) Indole derivatives.
MXPA03009206A (es) FORMULACIONES DE 3,7-DIAZABICICLO [3.3.1] COMO COMPUESTOS ANTIARRiTMICOS.
MXPA03004250A (es) Compuesto de lactama.
MXPA01012041A (es) Derivados de indol.
HK1040991A1 (zh) 2-雜芳基-3，4-二氫-2h-吡咯衍生物
HK1052925A1 (en) Substituted 1-aminobutan-3-ol derivatives.
ZA200206151B (en) Substituted amionomethyl-phenyl-cyclohexane derivatives.
MXPA03002649A (es) Derivado de benzodiazepina.
HK1049161A1 (en) Indole derivatives.
GB0130553D0 (en) 1,4-Dihydro-1,4-diphenylpyridine derivitives